This region encodes for the reverse transcriptase and protease enzymes, the targets of current antiretroviral drugs. Specific gene sequences are compared with that of a reference (wild-type ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Drug regimens now offer more potent, less toxic and more durable choices in the treatment of HIV disease than ever before. This has led to a need to consider the convenient, sequential use of ...

Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...

In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Given recent approvals and a promising pipeline, new biomedical HIV prevention tools for women have the potential to ...

Anemia prevalence was high in adult patients with HIV infection on HAART, with female sex, older age, and nonsuppressed viral load status identified as significant predictors.

DEPUTY Minister for Livestock and Fisheries, Mr Alexander Mnyeti, has urged citizens to report any information regarding ...

The 40th annual AIDS Walk Los Angeles will take place Sunday in a very different world than when it first started.

In June, we heard what could be this year’s biggest HIV breakthrough: a twice-yearly injection can prevent HIV infection. A ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...